RxDoctor Payments Data

Peter Bachwich, MD

Pulmonary Disease · Dublin, OHNPI 1366435463

Payments from drug & device makers

$205in general payments, 2019–2025

Across 10 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$69
  • Amgen$34
  • AstraZeneca$32
  • Pfizer$26
  • Electromed, Inc.$24
  • United Therapeutics Corporation$19

What the payments were for

  • Food & beverage$15676%
  • Education$4924%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$205 in reported general payments places this provider in the 20th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$124,178
Medicare patients
431
Services billed
1,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter505$455,419
Breztri AerosphereBudesonide/Glycopyr/Formoterol189$141,642
Spiriva RespimatTiotropium Bromide130$115,308
Breo ElliptaFluticasone/Vilanterol168$96,343
Spiriva HandihalerTiotropium Bromide83$83,810
Advair HfaFluticasone Propion/Salmeterol113$71,588
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr90$60,697
Arnuity ElliptaFluticasone Furoate134$47,265
SymbicortBudesonide/Formoterol Fumarate99$42,415
Stiolto RespimatTiotropium Br/Olodaterol Hcl48$36,394
Fluticasone-SalmeterolFluticasone Propion/Salmeterol210$33,627
DuleraMometasone/Formoterol58$29,854
Incruse ElliptaUmeclidinium Bromide49$26,955
Albuterol Sulfate HfaAlbuterol Sulfate772$25,674
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate95$16,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$69$686,679946 claims
AstraZenecaBreztri Aerosphere, Symbicort, Nexium$32$194,485305 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Dublin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →